Syndax announces Q3 earnings per share of 70 cents, slightly below consensus estimate of 71 cents.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 03 2025
0mins
Q3 Financial Performance: Syndax reported Q3 revenue of $45.9M, falling short of the consensus estimate of $47.97M, while holding $456.1M in cash and investments to support future profitability.
Product Demand and Sales: The company experienced strong demand for its products Revuforj and Niktimvo, achieving over $75M in combined net sales during the quarter.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like SNDX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on SNDX
Wall Street analysts forecast SNDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNDX is 39.11 USD with a low forecast of 27.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.550
Low
27.00
Averages
39.11
High
56.00
Current: 20.550
Low
27.00
Averages
39.11
High
56.00
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Syndax Partners with WODA to Expand Access to Revuforj in Multiple Regions
- Global Access Program: Syndax collaborates with WODA to launch a Managed Access Program aimed at expanding access to Revuforj in regions like Eurasia, the Middle East, Latin America, and Africa, potentially benefiting thousands of patients.
- Physician Experience Accumulation: This program not only provides a pathway for patients to access Revuforj but also allows more physicians to gain firsthand experience with the drug, supporting the long-term goal of establishing Revuforj as a standard treatment globally.
- FDA Approval Context: Revuforj is FDA-approved in the U.S. for treating difficult-to-treat acute leukemia, highlighting its significance in blood cancer treatment and expected to enhance Syndax's competitiveness in the global market.
- Role of WODA: WODA will provide Revuforj in over 150 countries, ensuring compliant and patient-focused distribution, further strengthening Syndax's influence in the global drug access landscape.
Continue Reading
Syndax Pharmaceuticals Inc. Offers 10.4% Annualized Return on $13 Put Options
- Options Selling Yield: Syndax Pharmaceuticals Inc.'s $13 put option offers a 10.4% annualized return, although the seller only acquires shares if the stock price falls by 39%, illustrating the complex relationship between risk and reward in options trading.
- Cost Basis Analysis: If the contract is exercised, the investor's cost basis would be $10.20 per share after accounting for the $2.80 premium, indicating that investors must carefully assess potential losses against current market price of $21.36.
- Volatility Consideration: With a trailing twelve-month volatility of 68% for Syndax, this provides investors a reference point for evaluating the risks of selling options, and combining this with fundamental analysis can help determine if the risk is worthwhile.
- Market Price Comparison: The current market price of $21.36 compared to the $13 strike price highlights the potential attractiveness of the options selling strategy, especially in a high volatility market, which may offer additional income opportunities for investors.
Continue Reading